Research across Plasma cell dyscrasias
Related studies from across the Plasma cell dyscrasias family.
Questions about Multiple Myeloma
Can linvoseltamab improve outcomes for patients with relapsed/refractory multiple myeloma compared to standard care?
Linvoseltamab may improve outcomes for relapsed/refractory multiple myeloma, with a 2025 indirect comparison showing longer survival and higher response rates than teclistamab, a similar bispecific antibody.
Full answer →Does teclistamab cause infections in patients with relapsed/refractory multiple myeloma based on real-world data?
Yes, real-world data shows teclistamab causes infections in about 45% of patients, with severe infections in about 23%, which is lower than clinical trial rates.
Full answer →What is the response rate for talquetamab and teclistamab combination in relapsed/refractory multiple myeloma?
The talquetamab and teclistamab combination shows a 79% overall response rate in relapsed/refractory multiple myeloma with extramedullary disease, based on the phase 2 RedirecTT-1 study.
Full answer →What are the infection rates for patients with relapsed/refractory multiple myeloma taking teclistamab?
In relapsed/refractory multiple myeloma patients taking teclistamab, about 57% experience any infection and about 28% have a severe (grade ≥3) infection, based on a meta-analysis.
Full answer →Do hematologists recommend using tocilizumab with bispecific antibodies for relapsed Multiple Myeloma?
Yes, hematologists recommend using tocilizumab to manage cytokine release syndrome (CRS) caused by bispecific antibodies in relapsed/refractory multiple myeloma, including prophylactic use in outpatient settings.
Full answer →What treatments were used in the case report for ultra-high-risk relapsed Multiple Myeloma?
The case report used a combination of ixazomib, lisaftoclax, and dexamethasone (ILD) as maintenance therapy after CAR-T cell therapy for ultra-high-risk relapsed multiple myeloma.
Full answer →Can Pomalyst be used to treat Kaposi sarcoma in addition to Multiple Myeloma?
Yes, Pomalyst is FDA-approved for both multiple myeloma and Kaposi sarcoma, including AIDS-related and HIV-negative cases.
Full answer →Is Revlimid approved for maintenance therapy after an autologous stem cell transplant for Multiple Myeloma?
Yes, Revlimid (lenalidomide) is FDA-approved as maintenance therapy after autologous stem cell transplant for multiple myeloma.
Full answer →